Inventor
TJOELKER LARRY W
US22 patents
⚠️ This page may combine multiple inventors who share the name “TJOELKER LARRY W”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ICOS CORP
13 patentsUS5532152AJul 2, 1996
Platelet-activating factor acetylhydrolase
ICOS CORP39 citations94
US6399571B1Jun 4, 2002
Chitinase chitin-binding fragments
ICOS CORP27 citations92
US6203790B1Mar 20, 2001
Platelet-activating factor acetylhydrolase
ICOS CORP21 citations92
US6045794AApr 4, 2000
Platelet-activating factor acetylhydrolase
ICOS CORP16 citations92
US5977308ANov 2, 1999
Platelet-activating factor acetylhydrolase
ICOS CORP18 citations92
US5847088ADec 8, 1998
Antibodies specific for platelet-activating factor acetylhydrolase
ICOS CORP18 citations92
US5698403ADec 16, 1997
Methods of detecting platelet-activating factor acetylhydrolase using antibodies
ICOS CORP22 citations92
US5641669AJun 24, 1997
Platelet-activating factor acetylhydrolase
ICOS CORP29 citations92
US6146625ANov 14, 2000
Platelet-activating factor acetylhydrolase
ICOS CORP14 citations81
US6099836AAug 8, 2000
Platelet-activating factor acetylhydrolase (PAF-AH) therapeutic uses
ICOS CORP14 citations81
US5605801AFeb 25, 1997
Methods of detecting lesions in the platelet-activating factor acetylhydrolase gene
ICOS CORP16 citations80
US6200951B1Mar 13, 2001
Chitinase chitin-binding fragments
ICOS CORP10 citations74
US5656431AAug 12, 1997
Platelet-activating factor acetylhydrolase
ICOS CORP15 citations73
OMEROS CORP
7 patentsUS11883493B2Jan 30, 2024
Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
OMEROS CORP1 citations72
US11027015B2Jun 8, 2021
Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
OMEROS CORP1 citations72
US10745274B1Aug 18, 2020
Nucleic acids encoding antibodies specifically binding to MASP-3
OMEROS CORP2 citations72
US10639369B2May 5, 2020
Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
OMEROS CORP2 citations72
US9677070B2Jun 13, 2017
Composition and method for diversification of target sequences
OMEROS CORP6 citations71
US9777065B2Oct 3, 2017
Anti-FZD10 monoclonal antibodies and methods for their use
OMEROS CORP0 citations50
US9346888B2May 24, 2016
Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
OMEROS CORP1 citations49